SynthesisThe Journal of allergy and clinical immunology2023
Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis.
Synthesis in The Journal of allergy and clinical immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 3 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- Efficacy and Safety of Biologics for Systemic Lupus Erythematosus (SLE): A Systematic Review and Network Meta-Analysis.Clinical reviews in allergy & immunology · 2025Pooled it
- Pooled it
- Efficacy of different biologics for treating chronic rhinosinusitis with nasal polyps: a network meta-analysis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025Pooled it
- Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: A target trial emulation.The Journal of allergy and clinical immunology · 2023Trial
- Pharmacovigilance signals of dupilumab among pediatric patients: A real‑world analysis based on the FAERS database.Human vaccines & immunotherapeutics · 2026Article
- Pediatric spontaneous-reporting patterns for biologics approved or used for asthma: Analysis of the FDA adverse event reporting system.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026Article
- Efficacy and Safety of Biologic Therapies for Uncontrolled Asthma: An Overview of Systematic Reviews.Pediatric pulmonology · 2026Review
- Tezepelumab in patients with asthma: a systematic review and meta-analysis of randomized controlled trials.Clinics (Sao Paulo, Brazil) · 2026Review
- Review
- Comparing the sleep benefits of Nature-Based Interventions: Evidence from a Bayesian Network meta-analysis.iScience · 2026Article
- [Mendelian Randomization Analysis of Potential Molecular Targets for Type 2 Airway Inflammatory Diseases].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2026Article
- The Therapeutic Role of Biologics in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): A Review of the Current Evidence.Therapeutics and clinical risk management · 2026Review
- Individualized precision therapy for severe asthma: clinical applications of biological agents and frontiers of cell therapy.Frontiers in immunology · 2026Review
- Case Report: Tezepelumab as rescue therapy in near-fatal asthma requiring extracorporeal membrane oxygenation.Frontiers in immunology · 2026Article
- Article
- Age-specific efficacy of biologics in severe asthma: a pediatric perspective.Frontiers in allergy · 2026Review
- Biologic outcomes in patients with severe asthma and clinically relevant allergy in the CHRONICLE study.The journal of allergy and clinical immunology. Global · 2026Article
- Tezepelumab: redefining TSLP blockade in severe asthma through mechanistic precision and translational pharmacology.Frontiers in pharmacology · 2026Review
- Comparison among stereotactic body radiation therapy, lobectomy, segmentectomy, and wedge resection for clinical stage I non-small cell lung cancer: a network meta-analysis.Journal of thoracic disease · 2025Article
- Efficacy of Dupilumab in a Woman With Severe Asthma Complicated by Eosinophilic Sinusitis and a Desire to Have a Baby: A Case Report.Clinical case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 3 countries.
Funding
Abstract
backgroundIt is unclear how the efficacy of tezepelumab, approved for the treatment of type 2 high and low asthma, compares to the efficacy of other biologics for type 2-high asthma.
objectivesWe sought to conduct an indirect comparison of tezepelumab to dupilumab, benralizumab, and mepolizumab in the treatment of eosinophilic asthma.
methodsThe investigators conducted a systematic review and Bayesian network meta-analyses. They identified randomized controlled trials indexed in PubMed, Embase, or Cochrane Central Register of Controlled Trials (CENTRAL) between January 1, 2000, and August 12, 2022. Outcomes included exacerbation rates, prebronchodilator FEV
resultsTen randomized controlled trials (n = 9201) met eligibility. Tezepelumab (relative risk: 0.63; 95% credible interval [CI]: 0.46-0.86) was associated with significantly lower exacerbation rates than benralizumab and larger improvements in FEV
conclusionsIn individuals with eosinophilic asthma, tezepelumab and dupilumab were associated with greater improvements (although below clinical thresholds) in exacerbation rates and lung function than benralizumab or mepolizumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.